UBS Group’s VectivBio Holding AG Ordinary Shares VECT Stock Holding History

UBS Group’s Portfolio VECT Stock Details VECT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-525,591	Closed	-$8.87M	–	10354
2023 Q2	$8.87M	Buy	525,591 +469,471	+837%	+$6.17M	﹤0.01%	2048
2023 Q1	$478K	Sell	56,120 -197,757	-78%	-$1.63M	﹤0.01%	4729
2022 Q4	$2.2M	Sell	253,877 -6,290	-2%	-$50.6K	﹤0.01%	3305
2022 Q3	$1.56M	Sell	260,167 -186	-0.1%	-$1.01K	﹤0.01%	3376
2022 Q2	$1.41M	Sell	260,353 -2,048	-0.8%	-$11K	﹤0.01%	3425
2022 Q1	$1.24M	Buy	262,401 +1,252	+0.5%	+$6.54K	﹤0.01%	3882
2021 Q4	$1.28M	Buy	261,149 +651	+0.2%	+$3.21K	﹤0.01%	4170
2021 Q3	$2.01M	Buy	260,498 +2,034	+0.8%	+$17.4K	﹤0.01%	3572
2021 Q2	$3.01M	Buy	+258,464	New	+$3.92M	﹤0.01%	3178

Other funds holding VECT

Regency Capital Management Honolulu, Hawaii $251M AUM 32.13% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

UBS Group's VECT Position: Q3 2023 in Review

UBS Group sold out of VectivBio Holding AG Ordinary Shares (VECT) in Q3 2023, closing a stake of 525,591 shares — an estimated $8.87M sold.

UBS Group first reported a position in VECT in Q2 2021 and held it in 9 quarters. The position peaked at $8.87M in Q2 2023. 2 funds tracked by Wall St. Rank hold VECT as of Q3 2023.

UBS Group reported no remaining VectivBio Holding AG Ordinary Shares position as of Q3 2023 after selling out during the quarter.
UBS Group sold 525,591 VectivBio Holding AG Ordinary Shares shares in Q3 2023, an estimated $8.87M.
UBS Group first reported a position in VectivBio Holding AG Ordinary Shares in Q2 2021 and held it in 9 quarters.
UBS Group's VectivBio Holding AG Ordinary Shares position peaked at $8.87M in Q2 2023.
2 funds tracked by Wall St. Rank held VectivBio Holding AG Ordinary Shares as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.